Our results showing that telomerase upregulation was not abolished by the PI3K/AKT pathway inhibition, suggests that personalized combined therapies associating PI3K and telomerase inhibitors or telomere G-quadruplex ligands should be considered to improve the radiosensitization in telomerase expressing high-grade gliomas. The gene discussed is AKT1; the disease is glioma.